secwatch.observer — SEC 8-K summary
======================================

Issuer:     OptimizeRx Corp (OPRX)
CIK:        0001448431
Form:       8-K
Filed at:   2026-03-05T23:59:59+00:00
Accession:  0001448431-26-000002
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 1.01, 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

OptimizeRx Q4 net income $5.0M, record adj EBITDA $12.0M; guides FY2026 rev $109-114M
--------------------------------------------------------------------------------

- Q4 revenue $32.2M (flat YoY); FY2025 revenue $109.4M (+19% YoY).
- Q4 GAAP net income $5.0M ($0.26/diluted share) vs net loss $0.1M in Q4 2024.
- Q4 adjusted EBITDA record $12.0M; FY2025 adj EBITDA $24.3M.
- FY2026 guidance: revenue $109-114M, adjusted EBITDA $21-25M.
- Board authorizes $10M share repurchase program effective Mar 12, 2026 through Mar 15, 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1448431/000144843126000002/0001448431-26-000002-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1448431/000144843126000002/oprx-20260305.htm
  HTML page:      https://secwatch.observer/filing/0001448431-26-000002

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer